原料药 API
具备 GMP / DMF 注册就绪度的原料药（API）与候选药物 · 每条标明用途、适应症与为何值得上线
Listing Logic · Why These Products
This category is not a mere directory listing—each product is selected against the four criteria below and comes with both its 'use' and 'why it is listed' so buyers can quickly assess fit. Products are drawn from Unibest's API & Candidates supply catalog and posted after dual qualification and demand screening.
We prioritize APIs already GMP/DMF-ready that can directly support regulatory filing, avoiding the compliance cost of building from scratch.
We target chronic long-term therapies, (WHO) public-health procurement and specialty must-have scenarios with low, predictable demand volatility.
We include first-in-class mechanisms, first approvals or molecules addressing resistance/unmet need, offering differentiated pricing power.
We also tag the number of linked intermediates—deeper in-house intermediate coverage means higher feasibility for scale-up and cost reduction.
Browse by Indication
Pick a class to see only APIs for that disease areaDiabetes, obesity, dyslipidemia, NASH and other metabolic diseases
Hypertension, heart failure, anticoagulation, chronic kidney disease
Solid tumours, haematologic malignancies, myeloproliferative diseases
Antiviral, antibacterial, antifungal, HIV / hepatitis
RA, psoriasis, atopic dermatitis, IBD
Epilepsy, pain, depression & anxiety, neurodegeneration
Acid-related, GI motility, diarrhoea, liver disease
COPD, asthma and other airway diseases
Menopausal symptoms, urological conditions
Glaucoma, ocular surface disease
Skin infection, dermatologic inflammation
Local anaesthesia, postoperative analgesia
Allergic rhinitis, urticaria
Companion-animal ectoparasiticides
Browse by Patent Expiry
The cliff decides when to act — filter by window firstCompound patent expired — generic sourcing and registration feasible
Cliff approaching — lock in API supply and filing schedule early
Mid-term opportunity — start process development and DMF work
Still on-patent — typically licensing or clinical supply
No expiry on file — request a patent assessment for this molecule
Expiry years are compiled from public sources and estimated on compound patents in major markets (US / EU). They exclude polymorph, process and formulation patents, term extensions and paediatric exclusivity. Values marked indicative are directional; values marked to-verify are inferred from filing era. Actual generic entry timing depends on national patent offices and the Orange Book.
Elinzanetant
Non-hormonal treatment of menopausal vasomotor symptoms (hot flashes)
A dual-receptor antagonist expected to further improve efficacy and sleep versus first-generation NK3 agents; a validated segment with large demand.
- CAS
- 929046-33-3
- Therapeutic Area
- Women's Health
- Target / Mechanism
- TACR1·TACR3
- Labeled Purity
- 99%+
Trelagliptin Succinate
Glycemic control in type 2 diabetes (once-weekly oral)
The world's first once-weekly oral DPP-4 inhibitor, markedly improving adherence; suited to fixed-dose combination with metformin and aligned with chronic-disease management policy.
- CAS
- 1029877-94-8
- Therapeutic Area
- Endocrine / Metabolism
- Target / Mechanism
- DPP4
- Labeled Purity
- 99%+
Orforglipron
Oral treatment of type 2 diabetes and obesity
An oral small-molecule (non-peptide) GLP-1 agonist, synthetically scalable versus peptide APIs, the most watched next-generation weight-management molecule.
- CAS
- 2212020-52-3
- Therapeutic Area
- Endocrine / Metabolism
- Labeled Purity
- 99%+
Vociprotafib
Targeted therapy of solid tumors carrying MAPK-pathway aberrations
An SHP2 inhibitor confronting KRAS/EGFR resistance, a core combination partner with KRAS inhibitors and EGFR antibodies.
- CAS
- 2172652-48-9
- Therapeutic Area
- Oncology / Targeted Therapy
- Labeled Purity
- 98%+
Vistusertib
Advanced solid tumors with PI3K/mTOR pathway aberrations
The mTOR pathway is a core resistance mechanism in breast and gynecologic cancers; combination regimens with endocrine therapy continue to advance.
- CAS
- 1009298-59-2
- Therapeutic Area
- Oncology / Targeted Therapy
- Target / Mechanism
- MTOR
- Labeled Purity
- 98%+
Afuresertib
Targeted therapy of multiple myeloma and various solid tumors
An oral pan-AKT inhibitor explored in both hematologic and solid tumors, a common targeted candidate within diagnosis-to-treatment integrated pathways.
- CAS
- 1047644-62-1
- Therapeutic Area
- Oncology / Hematology
- Target / Mechanism
- AKT2·AKT3·AKT1
- Labeled Purity
- 99%+
Tedizolid Phosphate
Acute bacterial skin and skin-structure infections (including MRSA)
A next-generation oxazolidinone with once-daily dosing and lower myelosuppression risk than peers, an important option against resistant Gram-positive bacteria.
- CAS
- 856867-55-5
- Therapeutic Area
- Anti-infective / Resistant Bacteria
- Labeled Purity
- 99%+
Supply source: Unibest API & Candidates supply catalog, sourced and delivered by Unibest. Therapeutic area, indication and selection rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability is subject to DMF/GMP documentation and the technical agreement confirmed at order.